GRACE trial testing relacorilant in Cushing’s meets primary goal
Among people with endogenous Cushing’s syndrome whose high blood pressure, or hypertension, dropped after five months on relacorilant, that response was maintained when the patients continued treatment for an additional period of three months. That’s according to new data from the randomized withdrawal phase of the Phase 3…